Psyence Biomedical Ltd. (PBM)

Psyence Biomedical Cash Flow Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	1.01	-51.16	-3.21	-1.86
Depreciation & Amortization	0	0	-	-
Stock-Based Compensation	-	0.32	0.22	0.33
Other Operating Activities	-4.36	49.07	-0.08	-
Change in Accounts Receivable	-0.1	0.11	-0.11	0.1
Change in Accounts Payable	-0.36	-1.04	1.66	0.03
Change in Other Net Operating Assets	0.07	-0.25	-0.07	0
Operating Cash Flow	-3.73	-2.95	-1.59	-1.4
Capital Expenditures	-0.01	-0.01	-	-
Other Investing Activities	-0.01	-	-	-0.03
Investing Cash Flow	-0.02	-0.01	-	-0.03
Short-Term Debt Issued	1	2.5	-	-
Total Debt Issued	1	2.5	-	-
Short-Term Debt Repaid	-	-0.15	-	-
Total Debt Repaid	-	-0.15	-	-
Net Debt Issued (Repaid)	1	2.35	-	-
Issuance of Common Stock	1.74	-	-	-
Other Financing Activities	6.41	-	1.17	-1.63
Financing Cash Flow	9.15	2.35	1.17	-1.63
Net Cash Flow	5.4	-0.6	-0.42	-3.06
Free Cash Flow	-3.74	-2.95	-1.59	-1.4
Free Cash Flow Per Share	-154.58	-270.67	-	-
Levered Free Cash Flow	-3.39	-1.71	-0.32	-
Unlevered Free Cash Flow	-3.39	-1.68	-0.32	-
Change in Net Working Capital	1.09	0.27	-1.48	-

Updated Jan 23, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q